FDA Rejects Over 88,000 Nicotine Products, Crackdown Continues

Aug.05.2022
FDA Rejects Over 88,000 Nicotine Products, Crackdown Continues
FDA rejects manufacturers of over 88,000 nicotine-containing products, including synthetic nicotine, without approval. Evaluation of over 350 products ongoing.

The FDA announced on Wednesday that they have sent "refuse to accept" letters to manufacturers of over 88,000 products containing laboratory-made nicotine.


Stephanie Keith/Getty Images (no translation needed as this is already in standard journalistic English)


Brian Kin, Director of the Center for Tobacco Products, revealed the progress of the FDA's regulation of non-tobacco nicotine sources (i.e. synthetic nicotine). The FDA was authorized earlier this year to regulate synthetic nicotine.


Regulatory gray area.


Brian King stated in a letter to unapproved makers of nasal snuff that "selling or distributing any new tobacco products without pre-market authorization in the U.S. market is illegal." The FDA has not approved any synthetic nicotine products for marketing.


According to regulations set by the FDA, as of July 13th, all unauthorized synthetic nicotine products are considered illegal. Therefore, technically, any manufacturer that has not received FDA approval cannot sell their products after that date.


However, the FDA also noted that it will continue to evaluate over 350 synthetic nicotine products. While many of these products (most of which are e-cigarettes) are technically not allowed to be sold, it is still unclear whether the FDA will remove them from the market upon evaluation. The FDA has exercised enforcement discretion for e-cigarettes containing tobacco-derived nicotine, allowing them to remain on shelves while continuing to weigh their sale.


A buildup process


Jonathan Foulds, a public health science professor specializing in tobacco addiction at Penn State College of Medicine, told Pulse that some manufacturers of synthetic nicotine electronic cigarettes are undoubtedly bad. They exploit regulatory loopholes to stay on the market, with their products mainly targeting teenagers.


Given the tight timeline for compiling evidence, other manufacturers may not have had the opportunity to submit applications to the FDA. "To be honest, I'd be surprised if any of them got authorization," he told Pulse. "It's a lot of work that requires a great deal of information and proper research, which simply can't be completed in just two months." He noted that even electronic cigarette manufacturers that use tobacco-derived nicotine have been unable to meet the FDA's evidence standards, despite having had years to apply for marketing orders.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the content. The purpose of translating this article is solely for industry discussions and research.


Due to limitations in translation ability, the translated article may not fully convey the intended meaning of the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions or positions.


The compilation of information belongs to the original media and author, and in the event of copyright infringement, please contact us for deletion.


He added, "If they are to withdraw from the market during the review by the agency, it would be fine by me, but they should have enough time to tidy up their applications.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
An exclusive 2Firsts investigation found an unpublished FDA update on e-cigarette marketing authorizations that mirrors market speculation, suggesting Glas’s application may have cleared internal review, though no official confirmation has been issued.
Regulations
Dec.21
Special Report| Vuse Gains as U.S. Cracks Down on Illegal Vapes, But a $590 Million China Export Shadow Looms
Special Report| Vuse Gains as U.S. Cracks Down on Illegal Vapes, But a $590 Million China Export Shadow Looms
The payoff is here: BAT’s Vuse has seized a rare regulatory vacuum to reverse its U.S. slide, capitalizing on a crackdown that seemingly compressed the illicit market to 54%. But the victory is fragile. A record $590 million export shock in October signals the gray market is striking back—pitting a fleeting compliance dividend against a massive inventory wall.
BAT
Dec.09
Exclusive | China Releases E-Cigarette Regulatory “Status Report”, First Comprehensive Disclosure of Oversight Framework and International Cooperation
Exclusive | China Releases E-Cigarette Regulatory “Status Report”, First Comprehensive Disclosure of Oversight Framework and International Cooperation
As 2025 draws to a close, China’s State Tobacco Monopoly Administration has released a white paper–style “Status Report” on e-cigarette regulation, systematically outlining its oversight framework, enforcement outcomes and international cooperation. 2Firsts provides exclusive in-depth reporting and analysis, offering insight into China’s regulatory logic and governance direction.
Dec.29 by 2Firsts Perspectives
China Boton Group Resumes Trading, Soars 55.56% to 52-Week High; Signs Land Acquisition Agreement with Shenzhen Government - Reuters/AP
China Boton Group Resumes Trading, Soars 55.56% to 52-Week High; Signs Land Acquisition Agreement with Shenzhen Government - Reuters/AP
China Boton Group (HK.3318) resumed trading on December 10, opening at 2.800 HKD and surging 55.56%.
Dec.10 by 2FIRSTS.ai
Product | FLONQ Parent Company Launches New Vaping Brand ROQY: Two Hybrid-Nicotine Devices Debut in Russia
Product | FLONQ Parent Company Launches New Vaping Brand ROQY: Two Hybrid-Nicotine Devices Debut in Russia
Alfabet Labs, the parent company of FLONQ, has recently launched its new vaping brand ROQY in Russia, debuting two products: ROQY L and ROQY M. Both devices use a hybrid nicotine formulation combining nicotine salts and freebase nicotine and are each available in 19 flavors. The two products are now on sale via the official ROQY website as well as multiple online and offline retailers across Russia.
Nov.19 by 2FIRSTS.ai
Malaysia health minister says court conviction over vape promotion sets key precedent for Act 852 enforcement
Malaysia health minister says court conviction over vape promotion sets key precedent for Act 852 enforcement
Malaysia’s Health Minister Datuk Seri Dr Dzulkefly Ahmad said the Putrajaya Magistrate’s Court decision to convict a known personality for promoting vape has set an important legal precedent for enforcing the Control of Smoking Products for Public Health Act (Act 852).
Jan.09 by 2FIRSTS.ai